Drug Patents owned by Shionogi Inc

1. Drug name - FETROJA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9238657 SHIONOGI INC Cephalosporin having catechol group
Nov, 2031

(9 years from now)

US10004750 SHIONOGI INC Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof
Sep, 2035

(12 years from now)

CN102203100B SHIONOGI INC Cephalosporin Having A Catechol Group
Oct, 2029

(7 years from now)

CN102203100A SHIONOGI INC Cephalosporin Having Catechol Group
Oct, 2029

(7 years from now)

CN106795176A SHIONOGI INC Salt Of Cephalosporin Derivatives, Its Crystalline Solid And Its Manufacturing Method
Sep, 2035

(12 years from now)

CN106795176B SHIONOGI INC Salts Of Cephalosporin Derivatives, Crystalline Solid Thereof, And Process For Producing The Same
Sep, 2035

(12 years from now)

IN293935B SHIONOGI INC Cephalosporin Having Catechol Group
Oct, 2029

(7 years from now)

IN201101800P4 SHIONOGI INC Cephalosporin Having Catechol Group
Oct, 2029

(7 years from now)

EP2341053A1 SHIONOGI INC Cephalosporin Having Catechol Group
Oct, 2029

(7 years from now)

EP2341053B1 SHIONOGI INC Cephalosporin Having Catechol Group
Oct, 2029

(7 years from now)

EP2341053A4 SHIONOGI INC Cephalosporin Having Catechol Group
Oct, 2029

(7 years from now)

EP2960244B1 SHIONOGI INC Cephalosporin Having Catechol Group
Oct, 2029

(7 years from now)

EP2960244A1 SHIONOGI INC Cephalosporin Having Catechol Group
Oct, 2029

(7 years from now)

EP3190115A4 SHIONOGI INC Salt Of Cephalosporin Derivative, Crystalline Solid Form Of Same And Method For Producing Same
Sep, 2035

(12 years from now)

EP3190115A1 SHIONOGI INC Salt Of Cephalosporin Derivative, Crystalline Solid Form Of Same And Method For Producing Same
Sep, 2035

(12 years from now)

EP3190115B1 SHIONOGI INC Salt Of Cephalosporin Derivative, Crystalline Solid Form Of Same And Method For Producing Same
Sep, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9949982 SHIONOGI INC Preparation containing cephalosporin having a catechol moiety Sep, 2035

(12 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 1GM BASE/VIAL POWDER;INTRAVENOUS Prescription

2. Drug name - MULPLETA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7601746 SHIONOGI INC Compounds exhibiting thrombopoietin receptor agonism
Sep, 2024

(1 year, 11 months from now)

US8889722 SHIONOGI INC Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
Jul, 2028

(5 years from now)

US8530668 SHIONOGI INC Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
Jan, 2030

(7 years from now)

CN1863783A SHIONOGI INC Compound Having Thrombopoietin Receptor Agonist Activity
Jul, 2013

(9 years ago)

CN103393678A SHIONOGI INC Medicine Composition Comprising Thrombopoietin Receptor Agonist Effect With The Optical Activity Of Compound And Intermediate Thereof
Jul, 2016

(6 years ago)

CN102796058A SHIONOGI INC Compound Having Thrombopoietin Receptor Agonism
Aug, 2024

(1 year, 10 months from now)

CN103130739B SHIONOGI INC Compound With Thrombopoietin Receptor Agonist Action
Aug, 2024

(1 year, 10 months from now)

CN102796058B SHIONOGI INC Compound With Thrombopoietin Receptor Agonist Action
Aug, 2024

(1 year, 10 months from now)

CN103130739A SHIONOGI INC Compound With Thrombopoietin Receptor Agonist Action
Aug, 2024

(1 year, 10 months from now)

CN101809008B SHIONOGI INC Medicine Composition Comprising Thrombopoietin Receptor Agonist Effect With The Optical Activity Of Compound And Intermediate Thereof
Jul, 2028

(5 years from now)

CN101809008A SHIONOGI INC Pharmaceutical Composition Containing Optically Active Compound Having Thrombopoietin Receptor Agonist Activity And Intermediate Thereof
Jul, 2028

(5 years from now)

CN103450110B SHIONOGI INC Pharmaceutical Composition Containing An Optically Active Compound Having Thrombopoietin Receptor Agonist Activity And Intermediate Thereof
Jul, 2028

(5 years from now)

CN103396313A SHIONOGI INC Medicine Composition Comprising Thrombopoietin Receptor Agonist Effect With The Optical Activity Of Compound And Intermediate Thereof
Jul, 2028

(5 years from now)

CN103450110A SHIONOGI INC Pharmaceutical Composition Containing Optically Active Compound Having Thrombopoietin Receptor Agonist Activity And Intermediate Thereof
Jul, 2028

(5 years from now)

CN103396313B SHIONOGI INC Medicine Composition Comprising Thrombopoietin Receptor Agonist Effect With The Optical Activity Of Compound And Intermediate Thereof
Jul, 2028

(5 years from now)

IN232700B SHIONOGI INC Compounds Having Thrombopoietin Receptor Agonism
Aug, 2024

(1 year, 10 months from now)

IN200600512P4 SHIONOGI INC Compounds Having Thrombopoietin Receptor Agonism
Aug, 2024

(1 year, 10 months from now)

EP1655291B1 SHIONOGI INC Compounds Having Thrombopoietin Receptor Agonism
Aug, 2024

(1 year, 10 months from now)

EP1655291A1 SHIONOGI INC Compounds Having Thrombopoietin Receptor Agonism
Aug, 2024

(1 year, 10 months from now)

EP1655291A4 SHIONOGI INC Compounds Having Thrombopoietin Receptor Agonism
Aug, 2024

(1 year, 10 months from now)

EP2184279A4 SHIONOGI INC Pharmaceutical Composition Containing Optically Active Compound Having Thrombopoietin Receptor Agonist Activity And Intermediate Thereof
Jul, 2028

(5 years from now)

EP2184279A1 SHIONOGI INC Pharmaceutical Composition Containing Optically Active Compound Having Thrombopoietin Receptor Agonist Activity And Intermediate Thereof
Jul, 2028

(5 years from now)

EP2184279B1 SHIONOGI INC Pharmaceutical Composition Containing Optically Active Compound Having Thrombopoietin Receptor Agonist Activity And Intermediate Thereof
Jul, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9427402 SHIONOGI INC Preparation for improving solubility of poorly soluble drug Sep, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
3MG TABLET;ORAL Prescription

3. Drug name - ULESFIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7294342 SHIONOGI INC Ectoparasite asphyxiator compositions and methods for their application May, 2024

(1 year, 7 months from now)

Drugs and Companies using BENZYL ALCOHOL ingredient

Treatment: Topical treatment of lice infestations

Dosage: LOTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
5% LOTION;TOPICAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.